Wiz
4.12.2023 14:02:28 CET | ACCESS Newswire | Press release
Cloud security provider grows its platform with acquisition of Raftt, deepening platform support for shift-left initiatives
NEW YORK, NY / ACCESSWIRE / December 4, 2023 / Cloud security leader Wiz has acquired Raftt, a cloud-native platform for developer collaboration. Recently, Wiz expanded its Cloud Native Application Protection Platform (CNAPP) to empower developers. Today's acquisition further enhances Wiz's Secure Cloud Development capabilities, which enable developers to build securely across the software development lifecycle.
Wiz's CNAPP - which is ranked #1 by customers and used by 40% of the Fortune 100 - already has a strong developer base: more than 50% of Wiz users sit outside the security function, reflecting the reality of how cloud security operations have become democratized. The addition of the Raftt team will allow Wiz to move even faster as the company continues to build and enhance its industry-leading platform, allowing security and development teams to proactively reduce their attack surface from build time to run time.
"The opportunity to be part of Wiz was one we couldn't pass up," said Roy Iarchy, Co-founder & CEO of Raftt. "At Raftt we lived and breathed the world of developers. We are extremely excited to put those superpowers to work and change the face of cloud security."
"Exceptional talent is the engine that fuels Wiz," said Assaf Rappaport, CEO & Cofounder, Wiz. "Wiz brings a unified view from runtime to development, clear risk analysis, and simplified operations that breaks down the operational silos between security and dev teams. The Raftt team will help us lean into our Secure Cloud Development strategy, introducing new capabilities for preventing costly production issues at the source."
For more on the Raftt acquisition, visit the Wiz blog.
About Wiz
Wiz secures everything organizations build and run in the cloud. Founded in 2020, Wiz is the fastest-growing software company in the world, scaling from $1M to $100M ARR in 18 months. Wiz enables hundreds of organizations worldwide, including 40 percent of the Fortune 100, to rapidly identify and remove critical risks in cloud environments. Its customers include Salesforce, Slack, Mars, BMW, Avery Dennison, Priceline, Cushman & Wakefield, DocuSign, Plaid, and Agoda, among others. Wiz is backed by Sequoia, Index Ventures, Insight Partners, Salesforce, Blackstone, Advent, Greenoaks, Lightspeed and Aglaé. Visit https://www.wiz.io for more information.
Contact Information
Tamar Harel
Head of US Office, STLV
tamar@shalomtelaviv.com
(347) 629-0609
SOURCE: Wiz
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/812726/wiz-acquires-raftt-bolsters-cnapp-offering-for-cloud-and-kubernetes-developers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence8.4.2026 16:00:00 CEST | Press release
DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs. As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow. "The latest version of SEE is designed to move research teams fro
Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications8.4.2026 14:00:00 CEST | Press release
Seasoned technology and life sciences leader to advance AI integration across medical communications FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services. Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization. Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom